How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls

The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.

No strings attached
Trump Administration Will Not Dictate Prices Despite Concerns From House Democrats

More from Pricing Debate

More from Market Access